Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$8.03
+2.7%
$7.19
$2.05
$8.72
$697.29M-0.46968,411 shs1.20 million shs
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$2.60
-5.8%
$1.99
$1.09
$7.22
$196.43M2.971.64 million shs1.31 million shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$10.63
+2.4%
$9.35
$2.21
$19.71
$736.40M0.451.09 million shs915,168 shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.47
+0.3%
$3.60
$1.26
$7.30
$822.81M1.96.34 million shs4.89 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-2.13%-4.63%-6.24%+44.01%+255.45%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-3.50%+23.21%+18.97%+102.94%-56.05%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
+2.77%0.00%+30.57%+166.15%-19.47%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
+1.76%+11.25%-25.27%+76.53%-31.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.3965 of 5 stars
4.52.00.00.02.12.50.6
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
1.4352 of 5 stars
3.22.00.00.01.01.70.0
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2.9729 of 5 stars
3.51.00.00.01.95.00.6
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
3.0806 of 5 stars
3.53.00.00.02.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$11.7546.33% Upside
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.33
Hold$8.00207.69% Upside
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.00
Buy$17.5064.63% Upside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
3.00
Buy$8.00130.55% Upside

Current Analyst Ratings Breakdown

Latest CCCC, PHAT, AMLX, and SANA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$10.00
7/3/2025
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$12.00
6/24/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold
6/24/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/24/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$17.00
6/24/2025
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$5.00
6/17/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $17.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
5/30/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$249K-2,875.55N/AN/A$1.88 per share4.27
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$34.24M5.40N/AN/A$2.45 per share1.06
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$114.04M6.61N/AN/A($5.72) per share-1.86
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$0.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$301.74M-$2.50N/AN/AN/AN/A-82.48%-70.15%11/6/2025 (Estimated)
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$105.32M-$1.58N/AN/AN/A-325.88%-53.91%-33.26%10/30/2025 (Estimated)
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%11/6/2025 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$266.76M-$1.06N/AN/AN/AN/A-91.96%-43.07%N/A

Latest CCCC, PHAT, AMLX, and SANA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.20-$0.16+$0.04-$0.39N/AN/A
8/7/2025Q2 2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.44-$0.46-$0.02-$0.46N/AN/A
8/7/2025Q2 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.38-$0.37+$0.01-$0.37$5.24 million$6.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$1.0212.65%N/AN/A N/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
8.72
8.72
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.06
5.06
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
2.38
2.35
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
2.47
2.47

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
12.30%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
8.73%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
24.10%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
30.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
20089.17 million78.20 millionOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15071.17 million64.96 millionOptionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11070.94 million53.85 millionOptionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
380237.81 million163.85 millionOptionable

Recent News About These Companies

Q3 EPS Forecast for Sana Biotechnology Raised by Analyst
Sana Biotechnology Reports Non-Cash Impairment Losses
Sana Biotech Bails on Factory in Old AT&T Call Center
Sana: Q2 Earnings Snapshot
Sana Biotechnology Announces Pricing of Public Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.03 +0.21 (+2.69%)
Closing price 04:00 PM Eastern
Extended Trading
$8.02 0.00 (-0.06%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$2.60 -0.16 (-5.80%)
Closing price 04:00 PM Eastern
Extended Trading
$2.58 -0.02 (-0.62%)
As of 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$10.63 +0.25 (+2.41%)
Closing price 04:00 PM Eastern
Extended Trading
$10.28 -0.35 (-3.30%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$3.47 +0.01 (+0.29%)
Closing price 04:00 PM Eastern
Extended Trading
$3.43 -0.04 (-1.15%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.